Peptides Derived from Glycoproteins H and B of Herpes Simplex Virus Type 1 and Herpes Simplex Virus Type 2 Are Capable of Blocking Herpetic Infection in vitro

Cetina-Corona, Abraham; López-Sánchez, Uriel; Salinas-Trujano, Juana; Méndez‐Tenorio, Alfonso; Barrón, Blanca Lilia; Torres-Flores, Jesús

doi:10.1159/000464134

Cited by 9 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three peptides-U-1, GST-removed-HR2 and HR2-18 were identified which show high binding affinity to SARS-CoV-2 spike protein. U-1 is an antiviral peptide (AVP) derived from the continuous residue stretches (CRSs) located at the surface of glycoprotein B (gB) (residues 224–243, ) which has high in vitro virucidal and antiviral activities against both herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) [ 29 ]. GST-removed-HR2 is a recombinant protein derived from the heptad repeat 2 (HR2) region (residues 1145–1192, ) which inhibits viral entry in Vero E3-luciferase assay (EC 50 = 2.15 μM) and functions as SARS-CoV entry inhibitors [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

et al. 2022

View full text Add to dashboard Cite

The appearance of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of effective antiviral therapeutics for coronavirus disease 2019 (COVID-19), a highly infectious disease caused by the virus, demands the search for alternative therapies. Most antiviral drugs known are passive defenders which must enter the cell to execute their function and suffer from concerns such as permeability and effectiveness, therefore in this current study, we aim to identify peptide inactivators that can act without entering the cells. SARS-CoV-2 spike protein is an essential protein that plays a major role in binding to the host receptor angiotensin-converting enzyme 2 and mediates the viral cell membrane fusion process. SARS vaccines and treatments have also been developed with the spike protein as a target. The virtual screening experiment revealed antiviral peptides which were found to be non-allergen, non-toxic and possess good water solubility. U-1, GST-removed-HR2 and HR2-18 exhibit binding energies of -47.8 kcal/mol, -43.01 kcal/mol, and -40.46 kcal/mol, respectively. The complexes between these peptides and spike protein were stabilized through hydrogen bonds as well as hydrophobic interactions. The stability of the top-ranked peptide with the drug-receptor is evidenced by 50-ns molecular dynamics (MD) simulations. The binding of U-1 induces conformational changes in the spike protein with alterations in its geometric properties such as increased flexibility, decreased compactness, the increased surface area exposed to solvent molecules, and an increase in the number of total hydrogen bonds leading to its probable inactivation. Thus, the identified antiviral peptides can be used as anti-SARS-CoV-2 candidates, inactivating the virus’s spike proteins and preventing it from infecting host cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Further assays led the authors to suggest that U-1 and U-2 may act in a postbinding step, possibly in upstream components of the entry machinery, and that CB-1 and CB-2 may interact with gC, the least herpes-conserved glycoprotein. In conclusion, further improvement of gH derived peptides are needed to diminish the concentration necessary to achieve satisfactory viral inhibition [138].…”

Section: Avps Designed From Herpes Simplex Virusmentioning

confidence: 99%

Antiviral peptides as promising therapeutic drugs

Boas

Campos

Berlanda

et al. 2019

Cell. Mol. Life Sci.

254

175

View full text Add to dashboard Cite

While scientific advances have led to large-scale production and widespread distribution of vaccines and antiviral drugs, viruses still remain a major cause of human diseases today. The ever-increasing reports of viral resistance and the emergence and re-emergence of viral epidemics pressure the health and scientific community to constantly find novel molecules with antiviral potential. This search involves numerous different approaches, and the use of antimicrobial peptides has presented itself as an interesting alternative. Even though the number of antimicrobial peptides with antiviral activity is still low, they already show immense potential to become pharmaceutically available antiviral drugs. Such peptides can originate from natural sources, such as those isolated from mammals and from animal venoms, or from artificial sources, when bioinformatics tools are used. This review aims to shed some light on antimicrobial peptides with antiviral activities against human viruses and update the data about the already well-known peptides that are still undergoing studies, emphasizing the most promising ones that may become medicines for clinical use.Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

show abstract

“…The CB‐1 peptide demonstrated less than 60% protection against 100 TCID 50 HSV‐1; however, the CB‐2 peptide showed greater than 90% protection at 500 μM. The CB‐1 peptide exhibited more than 90% protection, and the CB‐2 peptide showed less than 40% protection against 100 TCID 50 HSV‐2 at 250 μM (Cetina‐Corona et al, 2016 ).…”

Section: Protein or Peptide Decoy Targeting Hsv Fu...mentioning

confidence: 99%

A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus

Rahangdale,

Tender,

Balireddy

et al. 2023

Microbial Biotechnology

View full text Add to dashboard Cite

The health of the human population has been continuously challenged by viral infections. Herpes simplex virus (HSV) is one of the common causes of illness and can lead to death in immunocompromised patients. Existing anti‐HSV therapies are not completely successful in eliminating the infection due to anti‐viral drug resistance, ineffectiveness against the latent virus and high toxicity over prolonged use. There is a need to update our knowledge of the current challenges faced in anti‐HSV therapeutics and realize the necessity of developing alternative treatment approaches. Protein therapeutics are now being explored as a novel approach due to their high specificity and low toxicity. This review highlights the significance of HSV viral glycoproteins and host receptors in the pathogenesis of HSV infection. Proteins or peptides derived from HSV glycoproteins gC, gB, gD, gH and host cell receptors (HSPG, nectin and HVEM) that act as decoys to inhibit HSV attachment, entry, or fusion have been discussed. Few researchers have tried to improve the efficacy and stability of the identified peptides by modifying them using a peptidomimetic approach. With these efforts, we think developing an alternative treatment option for immunocompromised patients and drug‐resistant organisms is not far off.

show abstract

Peptides Derived from Glycoproteins H and B of Herpes Simplex Virus Type 1 and Herpes Simplex Virus Type 2 Are Capable of Blocking Herpetic Infection in vitro

Cited by 9 publications

References 42 publications

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19

Antiviral peptides as promising therapeutic drugs

A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus

Contact Info

Product

Resources

About